Synopsis
0
VMF
0
Canada
0
Weekly News Recap #Phispers
1. 0431, Mk
2. 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine
3. Anhydrous, Sitagliptin Phosphate
4. Januvia
5. Mk 0431
6. Mk-0431
7. Mk0431
8. Monohydrate, Sitagliptin Monophosphate
9. Monohydrate, Sitagliptin Phosphate
10. Monophosphate Monohydrate, Sitagliptin
11. Phosphate Anhydrous, Sitagliptin
12. Phosphate Monohydrate, Sitagliptin
13. Phosphate, Sitagliptin
14. Sitagliptin
15. Sitagliptin Monophosphate Monohydrate
16. Sitagliptin Phosphate Anhydrous
17. Sitagliptin Phosphate Monohydrate
1. 654671-78-0
2. Sitagliptin (phosphate)
3. Mk-0431
4. Chembl393336
5. 494p4635i6
6. Mk0431
7. (2r)-4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine Phosphate Salt
8. (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one;phosphoric Acid
9. (r)-3-amino-1-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl)-4-(2,4,5-trifluorophenyl)butan-1-one Phosphate
10. 1-butanone, 3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8h)-yl]-4-(2,4,5-trifluorophenyl)-, (3r)-, Phosphate (1:1)
11. Sitagliptin Monophosphate
12. Sitagliptin Phosphate Anhydrous
13. (3r)-3-amino-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)-1-butanone; Phosphoric Acid
14. Mk 0431
15. Sr-05000001748
16. Unii-494p4635i6
17. (2r)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8h)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine Phosphate Salt
18. Mk 431
19. Mk-0431 Phosphate
20. Schembl877069
21. Dtxsid10215789
22. Hy-13749a
23. Mfcd09952339
24. Akos015896098
25. Sitagliptin Phosphate [who-dd]
26. Ks-1214
27. 4-oxo-4-(3-(trifluoromethyl)-5,6-dihydro(1,2,4)triazolo(4,3-a)pyrazin-7(8h)-yl)-1-(2,4,5-trifluorophenyl)butan-2-amine Phosphate
28. Sitagliptin Monophosphate Anhydrous [mi]
29. 671s780
30. A835125
31. Sr-05000001748-2
32. Q27259224
33. Sitagliptin Phosphate Anhydrous Component Of Janumet
34. (3r)-3-amino-1-[5,6-dihydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazin-7(8h)-yl]-4-(2,4,5-trifluorophenyl)-1-butanone Phosphate
35. (3r)-3-azanyl-1-[3-(trifluoromethyl)-6,8-dihydro-5h-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-[2,4,5-tris(fluoranyl)phenyl]butan-1-one; Phosphoric Acid
36. 1,2,4-triazolo(4,3-a)pyrazine, 7-((3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl)-5,6,7,8-tetrahydro-3-(trifluoromethyl)-, Phosphate (1:1)
37. 1269630-53-6
38. 7-((3r)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl)-3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo(4,3-a)pyrazinemonophosphate
39. 7-(3r)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl-5,6,7,8-tetrahydro-3-(trifluoromethyl)-1,2,4-triazolo[4,3-a]pyrazine Phosphate
Molecular Weight | 505.31 g/mol |
---|---|
Molecular Formula | C16H18F6N5O5P |
Hydrogen Bond Donor Count | 4 |
Hydrogen Bond Acceptor Count | 14 |
Rotatable Bond Count | 4 |
Exact Mass | 505.09497466 g/mol |
Monoisotopic Mass | 505.09497466 g/mol |
Topological Polar Surface Area | 155 Ų |
Heavy Atom Count | 33 |
Formal Charge | 0 |
Complexity | 616 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 1 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Januvia |
PubMed Health | Sitagliptin (By mouth) |
Drug Classes | Antidiabetic |
Drug Label | JANUVIA Tablets contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Sitagliptin phosphate monohydrate is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahy... |
Active Ingredient | Sitagliptin phosphate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 25mg base |
Market Status | Prescription |
Company | Merck Sharp Dohme |
2 of 4 | |
---|---|
Drug Name | Sitagliptin phosphate |
Active Ingredient | Sitagliptin phosphate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 100mg base; 25mg; eq 50mg base; 100mg; 50mg; eq 25mg base |
Market Status | Tentative Approval |
Company | Mylan Pharms; Apotex; Sandoz; Sun Pharma Global; Watson Labs |
3 of 4 | |
---|---|
Drug Name | Januvia |
PubMed Health | Sitagliptin (By mouth) |
Drug Classes | Antidiabetic |
Drug Label | JANUVIA Tablets contain sitagliptin phosphate, an orally-active inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme. Sitagliptin phosphate monohydrate is described chemically as 7-[(3R)-3-amino-1-oxo-4-(2,4,5-trifluorophenyl)butyl]-5,6,7,8-tetrahy... |
Active Ingredient | Sitagliptin phosphate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 100mg base; eq 50mg base; eq 25mg base |
Market Status | Prescription |
Company | Merck Sharp Dohme |
4 of 4 | |
---|---|
Drug Name | Sitagliptin phosphate |
Active Ingredient | Sitagliptin phosphate |
Dosage Form | Tablet |
Route | oral; Oral |
Strength | eq 100mg base; 25mg; eq 50mg base; 100mg; 50mg; eq 25mg base |
Market Status | Tentative Approval |
Company | Mylan Pharms; Apotex; Sandoz; Sun Pharma Global; Watson Labs |
Hypoglycemic Agents
Substances which lower blood glucose levels. (See all compounds classified as Hypoglycemic Agents.)
Incretins
Peptides which stimulate INSULIN release from the PANCREATIC BETA CELLS following oral nutrient ingestion, or postprandially. (See all compounds classified as Incretins.)
Dipeptidyl-Peptidase IV Inhibitors
Compounds that suppress the degradation of INCRETINS by blocking the action of DIPEPTIDYL-PEPTIDASE IV. This helps to correct the defective INSULIN and GLUCAGON secretion characteristic of TYPE 2 DIABETES MELLITUS by stimulating insulin secretion and suppressing glucagon release. (See all compounds classified as Dipeptidyl-Peptidase IV Inhibitors.)
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
DA-1241, a GPR119 agonist, is in Phase 2 trials with sitagliptin, a DPP4 inhibitor, for steatohepatitis treatment.
Lead Product(s): DA-1241,Sitagliptin Phosphate
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: DA-1241
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2024
Lead Product(s) : DA-1241,Sitagliptin Phosphate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NeuroBo Reports Positive DA-1241 Safety Data and Opens Enrollment for Phase 2a
Details : DA-1241, a GPR119 agonist, is in Phase 2 trials with sitagliptin, a DPP4 inhibitor, for steatohepatitis treatment.
Brand Name : DA-1241
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2024
Details:
Through the acquisition, Cosmos will gain the license and rights for DIABIT-IS X, a drug that contains the active substance sitagliptin and is used in the treatment of type-2 diabetes.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: DIABIT-IS X
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Cosmos Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition December 20, 2023
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Cosmos Health
Deal Size : Undisclosed
Deal Type : Acquisition
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
Details : Through the acquisition, Cosmos will gain the license and rights for DIABIT-IS X, a drug that contains the active substance sitagliptin and is used in the treatment of type-2 diabetes.
Brand Name : DIABIT-IS X
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 20, 2023
Details:
Zituvio (Sitagliptin) tablets A is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: Zituvio
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus
Details : Zituvio (Sitagliptin) tablets A is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Brand Name : Zituvio
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2023
Details:
Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solution for diabetes.
Lead Product(s): Sitagliptin Phosphate,Pioglitazone,Metformin
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 27, 2023
Lead Product(s) : Sitagliptin Phosphate,Pioglitazone,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akums Gets DCGI Nod for Triple Combination Diabetes Medication
Details : Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solu...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 27, 2023
Details:
GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and safer treatment regimen.
Lead Product(s): Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: GMRx4
Study Phase: Phase IIProduct Type: Small molecule
Sponsor: CUREator
Deal Size: $1.0 million Upfront Cash: Undisclosed
Deal Type: Financing July 20, 2022
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...
Brand Name : GMRx4
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2022
Details:
Januvia (sitagliptin), a class of dipeptidyl peptidase (DPP4) inhibitors, is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: Januvia
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Sun Pharmaceutical Industries Limited
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2022
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Sun Pharmaceutical Industries Limited
Deal Size : Not Applicable
Deal Type : Not Applicable
Generics of MSD Diabetes Pill Set to Flood Market as Patent Expires
Details : Januvia (sitagliptin), a class of dipeptidyl peptidase (DPP4) inhibitors, is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.
Brand Name : Januvia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2022
Details:
Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: Sitagliptin-Generic
Study Phase: Phase IIIProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development
Details : Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.
Brand Name : Sitagliptin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2021
Details:
Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: Januvia
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 09, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
Details : Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.
Brand Name : Januvia
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 09, 2021
Details:
Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate).
Lead Product(s): Sitagliptin Phosphate
Therapeutic Area: Endocrinology Brand Name: Januvia
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 06, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Cadila Arm Receives US FDA Approval for Sitagliptin Base
Details : Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate).
Brand Name : Januvia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2021
3- (Trifluoromethyl)-5,6,7,8-tetrahydro [1,2,4] Tr...
CAS Number : 762240-92-6
End Use API : Sitagliptin Phosphate
About The Company : With a history spanning over three decades, IOL Chemicals and Pharmaceuticals Limited is an innovation-driven company that specializes in bulk drugs, intermedia...
(2,4,5-trifIuorophenyI)acetic acid
CAS Number : 209995-38-0
End Use API : Sitagliptin Phosphate
About The Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilit...
(3R)-3-Amino-1-[3-(trifIuoromethyI)-5,6,7,8-tetrah...
CAS Number : 486460-32-6
End Use API : Sitagliptin Phosphate
About The Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilit...
2,4,5-TrifIuoro-§-oxo-benzenebutanoic Acid Methyl...
CAS Number : 769195-26-8
End Use API : Sitagliptin Phosphate
About The Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilit...
3-(Trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]tria...
CAS Number : 762240-92-6
End Use API : Sitagliptin Phosphate
About The Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilit...
CAS Number : 764667-65-4
End Use API : Sitagliptin Phosphate
About The Company : Aptra Synthesis Private Limited, is a reliable and vertically integrated manufacturer of APIs and intermediates, boasting state-of-the-art manufacturing facilit...
3-(Trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]tria...
CAS Number : 762240-92-6
End Use API : Sitagliptin Phosphate
About The Company : Actis Generics Pvt Ltd is a fast emerging APIs (Active Pharmaceutical Ingredients) & Intermediates manufacturer & supplier in India set up by a group of young p...
(2Z)-4-Oxo-4-[3-(trifluoromethyl)-5,6-dihydro-[1,2...
CAS Number : 764667-65-4
End Use API : Sitagliptin Phosphate
About The Company : Actis Generics Pvt Ltd is a fast emerging APIs (Active Pharmaceutical Ingredients) & Intermediates manufacturer & supplier in India set up by a group of young p...
(3R)-3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrah...
CAS Number : 486460-32-6
End Use API : Sitagliptin Phosphate
About The Company : Actis Generics Pvt Ltd is a fast emerging APIs (Active Pharmaceutical Ingredients) & Intermediates manufacturer & supplier in India set up by a group of young p...
3-(Trifluoromethyl)-5,6,7,8- Tetrahydro-[1,2,4] Tr...
CAS Number : CAS-762240-92-6
End Use API : Sitagliptin Phosphate
About The Company : Almelo are the industry leaders in manufacturing advanced intermediates, Active Pharmaceutical Ingredients (APIs) and specialty fine chemicals. With a diverse p...
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : 25MG
Approval Date :
Application Number : 202327
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date :
Application Number : 202327
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Brand Name : JANUMET XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 1GM;EQ 50MG BASE
Approval Date : 2012-02-02
Application Number : 202270
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD : Yes
TE Code :
METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE
Brand Name : JANUMET XR
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 1GM;EQ 100MG BASE
Approval Date : 2012-02-02
Application Number : 202270
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : 25MG
Approval Date :
Application Number : 202487
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 25MG BASE
Approval Date :
Application Number : 214693
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET; ORAL
Dosage Strength : EQ 25MG BASE
Approval Date :
Application Number : 202473
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET; ORAL
Dosage Strength : EQ 50MG BASE
Approval Date :
Application Number : 202473
RX/OTC/DISCN :
RLD :
TE Code :
RLD :
TE Code :
Brand Name : SITAGLIPTIN PHOSPHATE
Dosage Form : TABLET; ORAL
Dosage Strength : EQ 100MG BASE
Approval Date :
Application Number : 202473
RX/OTC/DISCN :
RLD :
TE Code :
RLD : Yes
TE Code :
Brand Name : ZITUVIO
Dosage Form : TABLET;ORAL
Dosage Strength : 50MG
Approval Date : 2023-10-18
Application Number : 211566
RX/OTC/DISCN : RX
RLD : Yes
TE Code :
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info :
Registration Country : Italy
Brand Name : SITAGLIPTIN AND METFORMIN DR. REDDY'S
Dosage Form : Film-Coated Tablets
Dosage Strength : 50 mg/1,000 mg
Packaging : 56 UNITS (50+1000) MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
Regulatory Info :
Registration Country : Italy
Brand Name : SITAGLIPTIN AND METFORMIN DR. REDDY'S
Dosage Form : Film-Coated Tablets
Dosage Strength : 50 mg/850 mg
Packaging : 56 UNITS (50+850) MG - ORAL USE
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Italy
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Metformin hydrochloride; Sitagliptin
Brand Name : Sitagliptin Metformin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 50/1000mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Metformin hydrochloride; Sitagliptin
Brand Name : Sitagliptin Metformin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 50/500mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Metformin hydrochloride; Sitagliptin
Brand Name : Sitagliptin Metformin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 50/500mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Metformin hydrochloride; Sitagliptin
Brand Name : Sitagliptin Metformin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 50/850mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Metformin hydrochloride; Sitagliptin
Brand Name : Sitagliptin Metformin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 50/850mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Sitagliptin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 100mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Sitagliptin Zentiva
Dosage Form : Filmtabl
Dosage Strength : 100mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Sanofi is a pioneer in Diabetes Solutions, Human Vaccines, Innovative Drugs, Consumer Healthcare, and the new Genzyme.
Regulatory Info :
Registration Country : Switzerland
Brand Name : Sitagliptin Zentiva
Dosage Form : Film-Coated Tablets
Dosage Strength : 25mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?